| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3297319 | Gastroenterology | 2009 | 15 Pages |
Abstract
Biochemical and virologic responses were sustained for â¤3 years in approximately 25% of patients given a 48-week course of peginterferon alfa-2a, with or without lamivudine. The increased rate of HBsAg clearance in patients with HBeAg-negative chronic hepatitis B supports the use of peginterferon alfa-2a as a first-line treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Patrick Marcellin, Ferruccio Bonino, George K.K. Lau, Patrizia Farci, Cihan Yurdaydin, Teerha Piratvisuth, Rui Jin, Selim Gurel, Zhi-Meng Lu, Jian Wu, Matei Popescu, Stephanos Hadziyannis,